721PEfficacy of derazantinib (DZB) in patients (pts) with...

Annals of Oncology 2019 / 10 Vol. 30; Iss. Supplement

721PEfficacy of derazantinib (DZB) in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) expressing FGFR2-fusion or FGFR2 mutations/amplifications

Droz Dit Busset, M, Braun, S, El-Rayes, B, Harris, W P, Damjanov, N, Masi, G, Rimassa, L, Bhoori, S, Niger, M, Personeni, N, Braiteh, F, Lonardi, S, Engelhardt, M, Saulay, M, Schwartz, B, Shaib, W L,
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
30
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdz247.048
Date:
October, 2019
File:
PDF, 92 KB
english, 2019
Conversion to is in progress
Conversion to is failed